Compare PRU & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRU | ONC |
|---|---|---|
| Founded | 1875 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.5B | 34.8B |
| IPO Year | N/A | N/A |
| Metric | PRU | ONC |
|---|---|---|
| Price | $114.55 | $317.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | $116.80 | ★ $369.50 |
| AVG Volume (30 Days) | ★ 1.7M | 297.8K |
| Earning Date | 02-03-2026 | 11-06-2025 |
| Dividend Yield | ★ 4.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.27 | 0.58 |
| Revenue | ★ $57,598,000,000.00 | $4,972,687,000.00 |
| Revenue This Year | N/A | $895.40 |
| Revenue Next Year | $1.62 | $22.04 |
| P/E Ratio | ★ $15.89 | $525.08 |
| Revenue Growth | N/A | ★ 50.43 |
| 52 Week Low | $90.38 | $170.99 |
| 52 Week High | $123.88 | $385.22 |
| Indicator | PRU | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 63.46 | 44.90 |
| Support Level | $107.22 | $299.50 |
| Resistance Level | $118.31 | $326.77 |
| Average True Range (ATR) | 1.98 | 9.54 |
| MACD | 0.16 | -2.15 |
| Stochastic Oscillator | 66.06 | 42.41 |
Prudential Financial is one of the largest US life insurers, offering annuities, life insurance, and asset-management products. The United States and Japan are its two largest markets. Its US business contributed about 50% of adjusted 2024 earnings and includes institutional retirement (mostly pension risk transfer), individual retirement (annuities), group insurance, and individual life insurance. Its international business represented about 40% of adjusted earnings, with a strong market position in Japan, and the firm also has a presence in emerging markets like Brazil. The company's investment management business, PGIM, contributed approximately 10% of its 2024 adjusted earnings and has around $1.4 trillion in assets under management.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.